Molecular bases of osteoporosis in HIV: The role of the virus and antiretroviral therapy

被引：3
作者：
D. Gibellini
M. Borderi
E. Vanino
A. Clò
S. Morini
L. Calza
M. C. Re
Pl. Viale
机构：
[1] Department of Haematology and Oncological Sciences, Microbiology Section, University of Bologna, Bologna
[2] Department of Internal Medicine, Aging and Nephrology, Infectious Diseases Section, University of Bologna, Bologna
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2012年 / 10卷 / 4期
关键词：
Antiretrovirals; Bone; HIV; Osteopenia/osteoporosis; Virus;
D O I：
10.1007/s12018-012-9133-y
中图分类号：
学科分类号：
摘要：
In addition to immune system, HIV infection can determine the onset of functional dysfunctions of several organs and tissues such as central nervous system, cardiovascular system, kidney, and bone. It is noteworthy that HIV-infected individuals show an increased risk of bone mass loss with subsequent osteopenia and osteoporosis development. Interestingly, antiretroviral therapy is not able to tackle the bone derangement but, on the contrary, it can induce a progressive bone mass loss, especially when specific antiretroviral drugs are used. In this report, we summarized the HIV and antiretroviral-related mechanisms involved in the osteopenia and osteoporosis induction. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：236 / 245
页数：9
相关论文
共 123 条
  • [11] Manolagas S.C., Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis, Endocrine Reviews, 21, 2, pp. 115-137, (2000)
  • [12] Osteoporosis prevention, diagnosis, and therapy, JAMA, 285, pp. 785-795, (2001)
  • [13] Sambrook P., Cooper C., Osteoporosis, Lancet, 367, 9527, pp. 2010-2018, (2006)
  • [14] Haskelberg H., Carr A., Emery S., Bone turnover markers in HIV disease, AIDS Rev, 13, pp. 240-250, (2011)
  • [15] Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, WHO Technical Report Series 843, (1994)
  • [16] Kanis J.A., McCloskey E.V., Johansson H., Et al., Reference standard for the description of osteoporosis, Bone, 42, pp. 467-475, (2008)
  • [17] Nguyen N.D., Eisman J.A., Center J.R., Nguyen T.V., Risk factors for fracture in nonosteoporotic men and women, Journal of Clinical Endocrinology and Metabolism, 92, 3, pp. 955-962, (2007)
  • [18] Brainsky A., Glick H., Lydick E., Epstein R., Fox K.M., Hawkes W., Michael Kashner T., Zimmerman S.I., Magaziner J., The economic cost of hip fractures in community-dwelling older adults: A prospective study, Journal of the American Geriatrics Society, 45, 3, pp. 281-287, (1997)
  • [19] Lewis J.R., Hassan S.K.Z., Wenn R.T., Moran C.G., Mortality and serum urea and electrolytes on admission for hip fracture patients, Injury, 37, 8, pp. 698-704, (2006)
  • [20] Black D.M., Palermo L., Nevitt M.C., Et al., Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures, J Bone Miner Res, 10, pp. 890-902, (1995)
12345678910